AnaptysBio, Inc. (ANAB) Stock Analysis
Healthcare · Biotechnology
Sell if holding. At $64.64, A.R:R 0.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 7.8): -1.5; Thin upside margin: 6.2%.
AnaptysBio is a clinical-stage biotechnology company advancing rosnilimab (selective T cell depleter for RA with positive Phase 2b data) and ANB033 (CD122 antagonist in Phase 1b). Revenue comes from milestones and royalties from GSK (Jemperli/dostarlimab) and license fees from... Read more
Sell if holding. At $64.64, A.R:R 0.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 7.8): -1.5; Thin upside margin: 6.2%. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.9/10, moderate confidence.
Passes 4/7 gates (positive momentum, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 5d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomerGSK10-K Item 1A: 'Our existing collaboration with GSK and other collaborations are important to our business...If we are unable to maintain the GSK collaboration, or if this collaboration is not successful, our business could be adversely affected.'
Material Events(8-K, last 90d)
- 2026-04-20Item 2.01MEDIUMSpinoff of First Tracks Biotherapeutics completed April 20, 2026: AnaptysBio distributed all First Tracks shares pro rata to stockholders (1:1 ratio). First Tracks began trading on Nasdaq as TRAX. Separation and distribution agreement and transition services agreement executed.SEC filing →
- 2026-03-27Item 1.01LOWAnaptysBio and First Tracks Biotherapeutics entered into a Purchase Agreement with investors for an approximately 80M private placement of First Tracks common stock at 13.81 per share to close concurrent with the Spin-Off.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $64.64, A.R:R 0.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 7.8): -1.5; Thin upside margin: 6.2%. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $60.12. Score 5.9/10, moderate confidence.
Take-profit target: $68.66 (+6.2% upside). Prior stop was $60.12. Stop-loss: $60.12.
Thin upside margin: 6.2%; Leverage penalty (D/E 7.8): -1.5; Earnings in 5 days (event risk).
AnaptysBio, Inc. trades at a P/E of N/A (forward 12.3). TrendMatrix value score: 6.0/10. Verdict: Sell.
19 analysts cover ANAB with a consensus score of 4.3/5. Average price target: $79.
What does AnaptysBio, Inc. do?AnaptysBio is a clinical-stage biotechnology company advancing rosnilimab (selective T cell depleter for RA with...
AnaptysBio is a clinical-stage biotechnology company advancing rosnilimab (selective T cell depleter for RA with positive Phase 2b data) and ANB033 (CD122 antagonist in Phase 1b). Revenue comes from milestones and royalties from GSK (Jemperli/dostarlimab) and license fees from Vanda Pharmaceuticals; the company completed a spinoff of First Tracks Biotherapeutics in April 2026.